与CAZymes相关的方法来探索可通过向Bacteroides cellulosilyticus的方法减轻DSS诱导的大肠炎的甘氨酸
Xiaoxiang Gao1, FuSheng Xu1, Tangjun Li1
1State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China; School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122, China.
International journal of biological macromolecules
|December 14, 2023
概括
使用微生物碳水化合物活性酶 (CAZymes) 的向甘氨酸设计可以增加有益的肠道细菌,如 Bacteroides cellulosilyticus. 这种方法通过丰富特定的微生物并减轻小鼠结肠炎症状,有效治疗炎症性肠病 (IBD).
科学领域:
- 微生物学和免疫学
- 胃肠病学 胃肠病学
- 生物技术是生物技术.
背景情况:
- 炎症性肠病 (IBD) 治疗可以通过增加 Bacteroides cellulosilyticus 丰富度来改善.
- 目前微生物操纵的方法往往是无针对性的,昂贵的,复杂的,可能会增加有害细菌.
- 微生物碳水化合物活性酶 (CAZymes) 为精确的微生物调节提供了潜在的途径.
研究的目的:
- 开发一种基于CAZyme的方法来识别特定向和丰富有益肠道微生物的多糖.
- 评估设计的多糖在调节B. cellulosilyticus丰度和缓解IBD症状方面的有效性.
主要方法:
- 使用基于CAZyme的管道探索针对特定肠道微生物的多糖类.
- 作为向多糖的阿拉比诺 (AG) 的设计和合成.
- 在体外 (共同培养,发酵) 和体内 (老鼠模型) 评估AG对B. cellulosilyticus丰度的影响.
主要成果:
- 设计的阿拉比诺格拉克坦 (AG) 在体外和体外模型中显著丰富了B. cellulosilyticus的丰富性.
- 在小鼠模型中,AG补充有效地缓解了结肠炎和相关的临床症状.
- 证明AG直接调节B. cellulosilyticus水平并影响合作性微生物,导致大肠炎缓解.
结论:
- 以AG为例的有针对性的甘氨酸设计是增强特定肠道微生物 (如B. cellulosilyticus) 的有希望的策略.
- 这种方法通过选择性调节肠道微生物群,为治疗IBD提供了一种可行和有效的方法.
- 开发的甘氨酸设计管道提供了一种通过有针对性的微生物增强来改善疾病结果的新方法.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
01:17Drugs for Treatment of Diarrhea-Predominant IBS
179
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
179